Vancouver, B.C. and Boston, MA, April 26, 2016 – Imagin Medical (CSE: IME) (the “Company”) is pleased to announce that Ralph deVere White, M.D., has accepted the position of Chairman of the Company’s Scientific Medical Advisory Board. Dr. deVere White is Associate Dean for Cancer Programs at UC Davis School of Medicine and Director of the UC Davis Comprehensive Cancer Center where he is also a professor of urology. Dr. deVere White is a Past President of the Society of Urologic Oncology.
As previously announced, Imagin Medical entered into a licensing agreement on May 20, 2015, with the Lawrence Livermore National Laboratory (LLNL), a U.S. government technology discovery laboratory with 6300 employees, an operating budget of over $1.5B and multiple life science commercialization success stories. Working with Dr. Stavros Demos, formerly from LLNL and the inventor of the i/Blue Imaging System, Dr. deVere White evaluated the first prototypes of the technology, via an Internal Review Board (IRB) approval by the UC Davis Medical Center.
Ralph deVere White, M.D
Dr. deVere White received his medical degree from Dublin University in Dublin, Ireland, and completed an internship and residencies in surgery and urology at St. Vincent’s Hospital in Dublin and at Duke University Medical Center in Durham, NC. The author of more than 300 peer-reviewed scientific articles and book chapters, Dr. deVere White serves on the editorial boards of six international scientific journals. He is a member of the Clinical Society of Genitourinary Surgeons and an elected member of the prestigious American Association of Genitourinary Surgeons. He has been named multiple times as one of “The Best Doctors in America” and is one of four urologists serving as a volunteer consultant to the American Cancer Society’s on-line “Experts Answers” bulletin board for questions about prostate cancer.
Dr. deVere White is best known for his work in early bladder cancer detection. Jim Hutchens, President and CEO of Imagin Medical, states, “We are very excited to partner with Dr. deVere White. He is a true pioneer in the field of urology and we are extremely grateful that he will continue his clinical evaluation of our technology and provide guidance as the Company works to complete its development. This relationship is key to successfully commercialize and prepare the i/Blue Imaging System for the global marketplace.”
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.
ON BEHALF OF THE BOARD:
President & CEO
For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: [email protected]
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.